Vitamin D status in hospitalized COVID‑19 patients is associated with disease severity and IL-5 production.
25-hydroxyvitamin D
COVID-19
IL-5
SARS-CoV-2 infection
Vitamin D
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
13 09 2023
13 09 2023
Historique:
received:
13
06
2023
accepted:
23
08
2023
medline:
15
9
2023
pubmed:
14
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
There are many studies on the relationship between vitamin D and coronavirus disease 2019 (COVID-19), while the results are matters of debate and the mechanisms remain unknown. The present study was performed to assess the impact of serum 25-hydroxyvitamin D [25(OH)D] levels on the severity of disease in hospitalized COVID-19 patients and identify potential mechanisms of 25(OH)D alterations. A total of 399 hospitalized COVID-19 patients were recruited from three centers between December 19, 2022, and February 1, 2023. Medical history, laboratory examination, and radiologic data were retrospectively collected. The patients were divided into four groups based on disease severity. Serum 25(OH)D levels in the patients were determined by the electrochemiluminescence method and cytokines were detected by flow cytometry. The relationship between serum 25(OH)D status and the severity of COVID-19, and the correlation between 25(OH)D levels and cytokines in COVID-19 patients were assessed. Levels of 25(OH)D were significantly lower in the deceased group than in the other three groups (P < 0.05), and lower in the critical group than in the general group (P < 0.05). There were no significant differences in the 25(OH)D levels between the general and severe groups (P > 0.05). The levels of 25(OH)D (odds ratio = 0.986, 95% confidence interval: 0.973-0.998, P = 0.024) and IL-5 (odds ratio = 1.239, 95% confidence interval: 1.104-1.391, P = 0.04) were independent risk factors for the severity of COVID-19 disease upon admission. Serum 25(OH)D levels were able to predict the mortality of patients with COVID-19, and the predictive value was even higher when combined with IL-5 levels and eosinophil (Eos) count. Circulating 25(OH)D status correlated negatively with the expression of IL-5 (r=-0.262, P < 0.001) and was positively linked with CD8 This study found that the serum 25(OH)D status combined with IL-5 levels and Eos counts could be identified as a predictive factor for recognizing the risk of COVID-19 mortality. The serum 25(OH)D status in COVID-19 patients correlated negatively with the expression of IL-5. The potential mechanism for this relationship is worth further exploration.
Sections du résumé
BACKGROUND
There are many studies on the relationship between vitamin D and coronavirus disease 2019 (COVID-19), while the results are matters of debate and the mechanisms remain unknown. The present study was performed to assess the impact of serum 25-hydroxyvitamin D [25(OH)D] levels on the severity of disease in hospitalized COVID-19 patients and identify potential mechanisms of 25(OH)D alterations.
METHODS
A total of 399 hospitalized COVID-19 patients were recruited from three centers between December 19, 2022, and February 1, 2023. Medical history, laboratory examination, and radiologic data were retrospectively collected. The patients were divided into four groups based on disease severity. Serum 25(OH)D levels in the patients were determined by the electrochemiluminescence method and cytokines were detected by flow cytometry. The relationship between serum 25(OH)D status and the severity of COVID-19, and the correlation between 25(OH)D levels and cytokines in COVID-19 patients were assessed.
RESULTS
Levels of 25(OH)D were significantly lower in the deceased group than in the other three groups (P < 0.05), and lower in the critical group than in the general group (P < 0.05). There were no significant differences in the 25(OH)D levels between the general and severe groups (P > 0.05). The levels of 25(OH)D (odds ratio = 0.986, 95% confidence interval: 0.973-0.998, P = 0.024) and IL-5 (odds ratio = 1.239, 95% confidence interval: 1.104-1.391, P = 0.04) were independent risk factors for the severity of COVID-19 disease upon admission. Serum 25(OH)D levels were able to predict the mortality of patients with COVID-19, and the predictive value was even higher when combined with IL-5 levels and eosinophil (Eos) count. Circulating 25(OH)D status correlated negatively with the expression of IL-5 (r=-0.262, P < 0.001) and was positively linked with CD8
CONCLUSIONS
This study found that the serum 25(OH)D status combined with IL-5 levels and Eos counts could be identified as a predictive factor for recognizing the risk of COVID-19 mortality. The serum 25(OH)D status in COVID-19 patients correlated negatively with the expression of IL-5. The potential mechanism for this relationship is worth further exploration.
Identifiants
pubmed: 37705107
doi: 10.1186/s12985-023-02165-1
pii: 10.1186/s12985-023-02165-1
pmc: PMC10500897
doi:
Substances chimiques
Cytokines
0
Interleukin-5
0
Vitamin D
1406-16-2
IL5 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
212Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–9. https://doi.org/10.1038/nm1267 .
doi: 10.1038/nm1267
pubmed: 16007097
pmcid: 7095783
Bao W, Zhang X, Jin Y, et al. Factors Associated with the expression of ACE2 in human lung tissue: pathological evidence from patients with normal FEV(1) and FEV(1)/FVC. J Inflamm Res. 2021;14:1677–87. https://doi.org/10.2147/JIR.S300747 .
doi: 10.2147/JIR.S300747
pubmed: 33953595
pmcid: 8091594
Feiner Solis A, Avedillo Salas A, Luesma Bartolome MJ, et al. The Effects of vitamin D supplementation in COVID-19 patients: a systematic review. Int J Mol Sci. 2022;23(20). https://doi.org/10.3390/ijms232012424 .
Zhang X, Si G, Lu H, et al. SARS-CoV-2 omicron variant clearance delayed in breakthrough cases with elevated fasting blood glucose. Virol J. 2022;19(1):148. https://doi.org/10.1186/s12985-022-01877-0 .
doi: 10.1186/s12985-022-01877-0
pubmed: 36100916
pmcid: 9468532
Dong Y, Zhai W, Fang B, et al. A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in chinese participants infected with SARS-CoV-2 omicron variants. Front Pharmacol. 2022;13:988524. https://doi.org/10.3389/fphar.2022.988524 .
doi: 10.3389/fphar.2022.988524
pubmed: 36278166
pmcid: 9585249
Karonova TL, Andreeva AT, Golovatuk KA et al. Low 25(OH)D Level is Associated with severe course and poor prognosis in COVID-19. Nutrients 2021, 13(9). ARTN 3021. https://doi.org/10.3390/nu13093021
Aglipay M, Birken CS, Parkin PC, et al. Effect of high-dose vs Standard-Dose Wintertime vitamin D supplementation on viral Upper Respiratory Tract Infections in Young Healthy Children. JAMA. 2017;318(3):245–54. https://doi.org/10.1001/jama.2017.8708 .
doi: 10.1001/jama.2017.8708
pubmed: 28719693
pmcid: 5817430
Zdrenghea MT, Makrinioti H, Bagacean C, et al. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev Med Virol. 2017;27(1). https://doi.org/10.1002/rmv.1909 .
Benskin LL. A Basic Review of the preliminary evidence that COVID-19 risk and severity is increased in vitamin D Deficiency. Front Public Health. 2020;8:513. https://doi.org/10.3389/fpubh.2020.00513 .
doi: 10.3389/fpubh.2020.00513
pubmed: 33014983
pmcid: 7513835
Yilmaz K, Sen V. Is vitamin D deficiency a risk factor for COVID-19 in children? Pediatr Pulmonol. 2020;55(12):3595–601. https://doi.org/10.1002/ppul.25106 .
doi: 10.1002/ppul.25106
pubmed: 33017102
pmcid: 7675606
Sabico S, Enani MA, Sheshah E, et al. Effects of a 2-Week 5000 IU versus 1000 IU vitamin D3 supplementation on recovery of symptoms in patients with mild to moderate Covid-19: a Randomized Clinical Trial. Nutrients. 2021;13(7). https://doi.org/10.3390/nu13072170 .
Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. 2020;32(7):1195–8. https://doi.org/10.1007/s40520-020-01570-8 .
doi: 10.1007/s40520-020-01570-8
pubmed: 32377965
pmcid: 7202265
Alpcan A, Tursun S, Kandur Y. Vitamin D levels in children with COVID-19: a report from Turkey. Epidemiol Infect. 2021;149:e180. https://doi.org/10.1017/S0950268821001825 .
doi: 10.1017/S0950268821001825
pubmed: 34375576
Laires PA, Nunes C. Population-based estimates for high risk of severe COVID-19 Disease due to Age and Underlying Health Conditions. Acta Med Port. 2020;33(11):720–5. https://doi.org/10.20344/amp.14222 .
doi: 10.20344/amp.14222
pubmed: 32707029
Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–9. https://doi.org/10.1038/s41586-020-2588-y .
doi: 10.1038/s41586-020-2588-y
pubmed: 32717743
pmcid: 7477538
Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5. https://doi.org/10.1038/s41423-020-0402-2 .
doi: 10.1038/s41423-020-0402-2
pubmed: 32203188
pmcid: 7091858
Wang H, Tumes DJ, Hercus TR, et al. Blocking the human common beta subunit of the GM-CSF, IL-5 and IL-3 receptors markedly reduces hyperinflammation in ARDS models. Cell Death Dis. 2022;13(2):137. https://doi.org/10.1038/s41419-022-04589-z .
doi: 10.1038/s41419-022-04589-z
pubmed: 35145069
pmcid: 8831609
Wang Y, Wang J, Chen L, et al. Efficacy of vitamin D supplementation on COPD and asthma control: a systematic review and meta-analysis. J Glob Health. 2022;12:04100. https://doi.org/10.7189/jogh.12.04100 .
doi: 10.7189/jogh.12.04100
pubmed: 36520525
pmcid: 9754066
Lohia P, Kapur S, Patel P, et al. Letter to the editor: vitamin D levels in acute illness and clinical severity in COVID-19 patients. Respir Res. 2021;22(1):102. https://doi.org/10.1186/s12931-021-01703-1 .
doi: 10.1186/s12931-021-01703-1
pubmed: 33832495
pmcid: 8032551
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. https://doi.org/10.1210/jc.2011-0385 .
doi: 10.1210/jc.2011-0385
pubmed: 21646368
Ling SF, Broad E, Murphy R, et al. High-dose Cholecalciferol Booster Therapy is Associated with a reduced risk of mortality in patients with COVID-19: a cross-sectional Multi-Centre Observational Study. Nutrients. 2020;12(12). https://doi.org/10.3390/nu12123799 .
Gounari E, Chatzizisi O, Diza-Mataftsi E, et al. Potential prognostic value of intracellular cytokine detection by flow cytometry in pulmonary sarcoidosis. J Interferon Cytokine Res. 2013;33(5):261–9. https://doi.org/10.1089/jir.2012.0022 .
doi: 10.1089/jir.2012.0022
pubmed: 23656599
Popovska Jovicic B, Rakovic I, Gavrilovic J, et al. Vitamin D, Albumin, and D-Dimer as significant prognostic markers in early hospitalization in patients with COVID-19. J Clin Med. 2023;12(8). https://doi.org/10.3390/jcm12082825 .
Protas VV, Pogossyan GP, Li KG, et al. Plasma 25-Hydroxyvitamin D level and VDR gene single nucleotide polymorphism rs2228570 influence on COVID-19 susceptibility among the Kazakh ethnic Group-A pilot study. Nutrients. 2023;15(7). https://doi.org/10.3390/nu15071781 .
Slomski A. Vitamin D supplements don’t reduce COVID-19 risk. JAMA. 2022;328(16):1581doi. https://doi.org/10.1001/jama.2022.15486 .
doi: 10.1001/jama.2022.15486
Hernandez JL, Nan D, Fernandez-Ayala M, et al. Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J Clin Endocrinol Metab. 2021;106(3):e1343–53. https://doi.org/10.1210/clinem/dgaa733 .
doi: 10.1210/clinem/dgaa733
pubmed: 34932810
Mandal AKJ, Baktash V, Hosack T, et al. Vitamin D status may indeed be a prognosticator for morbidity and mortality in patients with COVID-19. J Med Virol. 2021;93(3):1225doi. https://doi.org/10.1002/jmv.26569 .
doi: 10.1002/jmv.26569
Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564–81. https://doi.org/10.1111/all.14364 .
doi: 10.1111/all.14364
pubmed: 32396996
Favaloro EJ, Lippi G. Recommendations for Minimal Laboratory Testing Panels in patients with COVID-19: potential for prognostic monitoring. Semin Thromb Hemost. 2020;46(3):379–82. https://doi.org/10.1055/s-0040-1709498 .
doi: 10.1055/s-0040-1709498
pubmed: 32279286
pmcid: 7295306
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. https://doi.org/10.1136/bmj.m1091 .
doi: 10.1136/bmj.m1091
pubmed: 32217556
pmcid: 7190011
Pala D, Pistis M. Anti-IL5 drugs in COVID-19 patients: role of Eosinophils in SARS-CoV-2-Induced Immunopathology. Front Pharmacol. 2021;12:622554. https://doi.org/10.3389/fphar.2021.622554 .
doi: 10.3389/fphar.2021.622554
pubmed: 33767626
pmcid: 7985166
Schoenmakers I, Fraser WD, Forbes A. Vitamin D and acute and severe illness - a mechanistic and pharmacokinetic perspective. Nutr Res Rev. 2023;36(1):23–38. https://doi.org/10.1017/S0954422421000251 .
doi: 10.1017/S0954422421000251
pubmed: 34369338
Liu Y, Zhang C, Huang F, et al. Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev. 2020;7(6):1003–11. https://doi.org/10.1093/nsr/nwaa037 .
doi: 10.1093/nsr/nwaa037
pubmed: 34676126
pmcid: 7107806
Singh SK, Jain R, Singh S. Vitamin D deficiency in patients with diabetes and COVID- 19 infection. Diabetes Metab Syndr. 2020;14(5):1033–5. https://doi.org/10.1016/j.dsx.2020.06.071 .
doi: 10.1016/j.dsx.2020.06.071
pubmed: 32640414
pmcid: 7332933
Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging. 2020;12(12):11245–58. https://doi.org/10.18632/aging.103372 .
doi: 10.18632/aging.103372
pubmed: 32633729
pmcid: 7343511
Sun Y, Dong Y, Wang L, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. J Autoimmun. 2020;112:102473. https://doi.org/10.1016/j.jaut.2020.102473 .
doi: 10.1016/j.jaut.2020.102473
pubmed: 32439209
pmcid: 7180376
Chen R, Sang L, Jiang M, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol. 2020;146(1):89–100. https://doi.org/10.1016/j.jaci.2020.05.003 .
doi: 10.1016/j.jaci.2020.05.003
pubmed: 32407836
pmcid: 7212968
Bilezikian JP, Bikle D, Hewison M, et al. MECHANISMS IN ENDOCRINOLOGY: vitamin D and COVID-19. Eur J Endocrinol. 2020;183(5):R133–47. https://doi.org/10.1530/EJE-20-0665 .
doi: 10.1530/EJE-20-0665
pubmed: 32755992
pmcid: 9494342
Chiodini I, Gatti D, Soranna D, et al. Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes. Front Public Health. 2021;9:736665. https://doi.org/10.3389/fpubh.2021.736665 .
doi: 10.3389/fpubh.2021.736665
pubmed: 35004568
pmcid: 8727532
Poddighe D, Kovzel E. Impact of anti-type 2 inflammation biologic therapy on COVID-19 clinical course and outcome. J Inflamm Res. 2021;14:6845–53. https://doi.org/10.2147/JIR.S345665 .
doi: 10.2147/JIR.S345665
pubmed: 34934335
pmcid: 8684423
Zhou Y, Qiu Y, Bao W, et al. Evaluating the effects of vitamin D level on airway obstruction in two asthma endotypes in humans and in two mouse models with different intake of vitamin D during early-life. Front Immunol. 2023;14:1107031. https://doi.org/10.3389/fimmu.2023.1107031 .
doi: 10.3389/fimmu.2023.1107031
pubmed: 36793727
pmcid: 9922677
Zhou Y, Xue Y, Bao A, et al. Effect of vitamin D Deficiency and Supplementation in Lactation and Early Life on allergic airway inflammation and the expression of Autophagy-Related genes in an Ovalbumin Mouse Model. J Inflamm Res. 2021;14:4125–41. https://doi.org/10.2147/JIR.S321642 .
doi: 10.2147/JIR.S321642
pubmed: 34466017
pmcid: 8403027